“…, implanted at the time of brain metastases (BM) resection and one evaluating the combined use of erlotinib, a tyrosine kinase EGF receptor (EGFR) inhibitor, with whole-brain irradiation (WBI) for BM resulting from non-small-cell lung cancer [1][2][3]. A prospective single-arm Phase II trial of one to three BM treated with surgical resection, Gliadel implantation, stereotactic radiotherapy (RT) and deferred WBI evaluated neurocognitive outcome in 59 patients [1].…”